Milan Scheidegger

Leader of Psychedelic Research at University of Zurich

Data updated

Papers

22 publications

Trials

1 clinical trials

Research Footprint

Milan Scheidegger appears in 22 tracked papers (2015–2026) and 1 clinical trial, most studied alongside Ayahuasca, Psilocybin and DMT, across Healthy Volunteers, Depressive Disorders and Neuroimaging & Brain Measures.

Most-cited paper: Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers (320 citations).

Frequent co-authors: Dominik Dornbierer, Daniel Meling and Anne Aicher.

Background & Research

Milan Scheidegger leads the Psychedelic Research & Therapy Development group in Zurich. With a background in medicine, neuroscience, and philosophy, he develops novel formulations for DMT and 5-MeO-DMT. His translational research explores how psychedelic-induced plasticity can be harnessed to facilitate healing and transformative experiences in both clinical and naturalistic settings.

Key Impact

Investigates how psychedelics enhance neurobehavioral plasticity and support psychotherapy.

22

Research Papers

View publications →

1

Clinical Trials

Explore trials →

Collaboration Network

28 collaborators· click a node to visit their profile

Full network →

Compounds

AyahuascaPsilocybinDMTPlacebo

Topics

Healthy VolunteersDepressive DisordersNeuroimaging & Brain MeasuresAnxiety DisordersInterpersonal Functioning & Social ConnectednessSet & SettingPersonality & Trait FactorsSafety & Risk ManagementMedicinal Chemistry & Drug DevelopmentSubstance Use Disorders (SUD)Equity and EthicsCreativityImplementation & Service DeliveryPublic Health, Prevention & Behaviour ChangeChronic PainPTSDBipolar DisorderSchizophreniaMajor Depressive Disorder (MDD)

Top Collaborators

Affiliations

Institutions, companies, and organisations Milan Scheidegger is associated with.

University of Zurich

academic

Within the 'Department of Psychiatry, Psychotherapy and Psychosomatics' at the University of Zurich, Dr Milan Scheidegger is leading a team conducting psychedelic research and therapy development. Researchers here are investigating the therapeutic potential of psychedelics to reverse maladaptive neurobehavioral patterns in stress-related mood disorders and to enhance psychotherapeutic learning capabilities.

View stakeholder →

Reconnect Labs

Private Biotech

Reconnect Labs AG is a Swiss clinical-stage company and University of Zurich spin-off developing precision psychopharmacology therapeutics, including sublingual DMT/harmine, sublingual 5-MeO-DMT, and sublingual dexmedetomidine. Founded in 2021 by Dr. Davor Kosanic (CEO) and co-founders from the Psychiatric University Clinic Zurich and ETH Zurich, building on ~30 years of in-human psychedelic research. The company raised CHF 22M+ (CHF 12M equity across Seed 2021 and Series A 2023–2025; CHF 10M in competitive grants from investors including Esperante Ventures, Lionheart Ventures, Negev Capital, and Noetic Fund) before emerging from stealth in August 2025. Their microcarrier-based transmucosal delivery platform (exclusively licensed) dramatically reduces inter-subject PK variability for DMT/harmine vs. oral ayahuasca and eliminates vomiting. RE03 (sublingual dexmedetomidine for insomnia in PTSD) is the most advanced programme with Swissmedic approval and FDA accelerated pathway confirmed.

View stakeholder →